Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutics, Targets, and Chemical Biology

Differential Contextual Responses of Normal Human Breast Epithelium to Ionizing Radiation in a Mouse Xenograft Model

Philip J. Coates, M. Virginia, C.L. Appleyard, Karen Murray, Caroline Ackland, June Gardner, Douglas C. Brown, Dougal J.A. Adamson, Lee B. Jordan, Colin A. Purdie, Alastair J. Munro, Eric G. Wright, John A. Dewar and Alastair M. Thompson
Philip J. Coates
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Virginia
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.L. Appleyard
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karen Murray
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Ackland
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
June Gardner
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas C. Brown
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dougal J.A. Adamson
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee B. Jordan
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin A. Purdie
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair J. Munro
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric G. Wright
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Dewar
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair M. Thompson
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
1Centre for Oncology and Molecular Medicine, and Departments of 2Surgery, 3Oncology, and 4Pathology, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom; and 5Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-10-1118 Published December 2010
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Radiotherapy is a key treatment option for breast cancer, yet the molecular responses of normal human breast epithelial cells to ionizing radiation are unclear. A murine subcutaneous xenograft model was developed in which nonneoplastic human breast tissue was maintained with the preservation of normal tissue architecture, allowing us to study for the first time the radiation response of normal human breast tissue in situ. Ionizing radiation induced dose-dependent p53 stabilization and p53 phosphorylation, together with the induction of p21(CDKN1A) and apoptosis of normal breast epithelium. Although p53 was stabilized in both luminal and basal cells, induction of Ser392-phosphorylated p53 and p21 was higher in basal cells and varied along the length of the ductal system. Basal breast epithelial cells expressed ΔNp63, which was unchanged on irradiation. Although stromal responses themselves were minimal, the response of normal breast epithelium to ionizing radiation differed according to the stromal setting. We also demonstrated a dose-dependent induction of γ-H2AX foci in epithelial cells that was similarly dependent on the stromal environment and differed between basal and luminal epithelial cells. The intrinsic differences between human mammary cell types in response to in vivo irradiation are consistent with clinical observation that therapeutic ionizing radiation is associated with the development of basal-type breast carcinomas. Furthermore, there may be clinically important stromal–epithelial interactions that influence DNA damage responses in the normal breast. These findings demonstrate highly complex responses of normal human breast epithelium following ionizing radiation exposure and emphasize the importance of studying whole-tissue effects rather than single-cell systems. Cancer Res; 70(23); 9808–15. ©2010 AACR.

Introduction

Adjuvant radiotherapy is commonly used to improve outcomes for patients with early breast cancer (1). Breast conservation (tumor excision followed by breast radiotherapy) is now used in 70% of operable patients and provides comparable survival to mastectomy (1). Indeed, radiotherapy to the residual breast tissue after conservative surgery prevents recurrence both for invasive breast cancer and for ductal carcinoma in situ, a condition that now accounts for 25% of breast cancer diagnoses (1). Advances in radiotherapy for breast cancer include hypofractionation (2), limited fields of radiation exposure (3), and intraoperative radiotherapy (4, 5). The use of radiotherapy, particularly targeted approaches, is likely to increase (6).

Given the importance of radiotherapy in the management of breast cancer, little is known about the mechanistic and dose-limiting effects of radiation upon normal breast tissue, compounded by the considerable heterogeneity of normal tissue responses (7). These differences in tissue responses may result from genetically determined factors that influence cellular radiosensitivity or the microenvironment (7, 8).

The TP53 gene encodes the p53 protein, which integrates multiple cellular stress signals including those induced by radiation and via posttranslational modification (including phosphorylation, acetylation, and methylation of specific residues) triggers growth arrest or programmed cell death (apoptosis) by modulating gene expression (9–11). p53 can also trigger cell death independently of transcription and has wide-ranging effects on the development and normal function of organisms, including effects on cellular senescence, autophagy, and glucose metabolism (12, 13). Cells in vivo demonstrate tissue-specific p53 pathway responses to radiation-induced DNA damage (14–20). Actively proliferating cells within self-renewing tissues show stabilization and transcriptional activation of p53 that leads to apoptosis. In contrast, some nonproliferating tissues show neither p53 stabilization nor apoptosis. An intermediate group of nonproliferative tissues shows p53 induction but not apoptosis (18, 19). These tissue-specific p53 pathway responses to ionizing radiation are genotype dependent (14). In the breast, basal and luminal mammary cells propagated and maintained as isolated cells or as small tissue fragments in vitro exhibit distinct responses to ionizing radiation. Basal cells exhibit transitory growth arrest, whereas luminal cells show a more prolonged period of arrest (21). However, these in vitro studies rely on the use of specific culture conditions, which themselves influence radiation responses (22). Thus, in vitro experiments designed to predict normal tissue responses suffer from a variety of artifacts that limit their usefulness (7).

The responses of normal human tissues to ionizing radiation in situ have been studied in skin biopsies from patients receiving radiotherapy for internal tumors such as breast and prostate (23–25), but other models of normal human tissue responses to radiation that preserve tissue architecture and cellular interactions with the stromal environment are currently lacking. The aim of this study was to develop a xenograft model of normal mammary tissues derived from women with breast cancer at the time of surgery (26, 27) and apply the model to investigate the molecular pathways that are activated by ionizing radiation in human mammary tissues in vivo. We sought to test the hypothesis that distinct cell types respond differently to the same radiation dose and that the surrounding stromal context influences these epithelial responses. Our model preserves the anatomic relationships of ductal/lobular units with the surrounding human breast stroma and for the first time permits time-course and dose-response studies of different cell types within their normal 3-dimensional architecture following in vivo irradiation.

Methods

Macroscopically, normal breast tissue from 20 consenting patients with primary, previously untreated stage I or stage II breast carcinoma was excised from the breast adjacent to the excision cavity at the time of wide local excision. Tissues were transported in a sterile container, stripped of excess fat, divided into 2 × 1 × 1-mm3 fragments and placed in Dulbecco's modified Eagle's medium until implantation. Developing and extending previous methods that maintain long-term tissue viability and the anatomic relationships of ductal/lobular units (26, 27), breast tissue fragments were implanted under general anesthesia subcutaneously into the flanks of 6 to 12 SCID mice per patient and used to study the molecular pathways activated in response to ionizing radiation in vivo.

Mice were housed under normal conditions, and 4 days later, whole-body γ-irradiation from a CIS Bio International 637-cesium source was delivered at a metered dose of 0 gray (Gy) (controls) and 2 or 5 Gy to duplicate animals (dose rate = 0.4 Gy/min) for each patient sample. The xenografted human tissues were harvested 4 hours after radiation exposure, for which previous in vivo studies have shown near maximal stabilization of p53 together with the activation of downstream signaling pathways and induction of apoptosis (14, 18). In 2 patients, sufficient mammary tissue was available to allow additional comparison of 1- and 4-hour time points after exposure to either 2 or 5 Gy. Sections of formalin-fixed, paraffin-embedded human tissues were stained with hematoxylin and eosin for initial histopathologic examination to confirm the presence of normal breast tissue.

All experiments were performed with permission of the Local (Human) Research Ethics Committee and Animal Licensing Authorities under strict codes of aseptic practice. Xenograft studies were carried out in accordance with the UKCCCR guidelines.

Immunohistochemistry

Sections (4 μm) were stained with an avidin–biotin complex peroxidase technique (Vector Elite reagents; Vector Laboratories Ltd, Peterborough, UK) according to the manufacturer's instructions and detected with diaminobenzidine containing 5 mmol/L of imidazole. Antigen retrieval was performed by boiling for 15 minutes in 10 mmol/L of citrate, pH 6.0, except for γ-H2AX staining for which antigen retrieval was not performed (Table 1). Sections were counterstained with hematoxylin and viewed under a light microscope. For p53, phospho-p53, p21, and Mdm2, staining was quantified using the histoscore, for which staining intensity is divided into 5 groups (0–4, where 0 is negative and 4 is very strongly stained) and the percentage of cells in each category is multiplied by the category number and values added together, providing a continuous score that ranges from 0 to 400 (28). For measurements of apoptosis, the percentages of cells stained for activated caspase-3 were recorded.

View this table:
  • View inline
  • View popup
Table 1.

Primary antibodies

Results

Tissue procurement

Staining with hematoxylin and eosin showed that normal breast epithelial and stromal histologic architecture was preserved in at least 1 of 2 duplicate xenografts from each dose and time point in tissue derived from 10 of the 20 patients. The remaining patient samples were excluded, as not all dose or time points contained sufficient breast epithelium and/or the implanted tissues showed poor morphology. As a second screening tool, all samples that contained sufficient epithelium with good morphology were stained for HIF1α to identify areas of xenografts with suboptimal oxygenation, seen in focal areas of individual tissue fragments in 20% of individual samples. Because all of these samples contained sufficient epithelium in other areas of the section that were not stained for HIF1α, no additional sections had to be excluded from analysis, but all regions of individual tissue fragments with HIF1α staining in control or irradiated mice were considered hypoxic and these specific areas were therefore excluded from further analysis. Indeed, nuclear HIF1α was associated with weak staining for p53 in sham-irradiated animals, in keeping with the concept that hypoxia is an inducer of p53 stabilization (11).

Cell type and dose response

Xenograft material from 10 patients was successfully examined for dose-dependent radiation responses at 4 hours postirradiation. Staining for p53 was exclusively nuclear, and cytoplasmic staining was not seen. Immunostaining demonstrated a clear dose-dependent increase in p53 in xenografts 2- or 5-Gy irradiation compared with control tissues (Table 2). Responses to irradiation were prominent in breast epithelium compared with a minimal response in breast stromal cells (Fig. 1), even though the dose received by each cell in the tissue was the same. A quantitative analysis demonstrated the dose-dependent induction and stabilization of p53, together with p53 phosphorylation at Ser15 and Ser392, induction of p21(CDKN1A), and induction of Mdm2 (Table 2 and Fig. 2). Apoptosis, measured by the cleavage of caspase-3, also showed a dose-dependent increase. These data also showed considerable heterogeneity of response, demonstrated by the variable p53 response in tissues from individual patients (Supplementary Fig. S1; note also the range of values in Table 2). Staining for ΔNp63 was seen only in basal epithelium and was unaltered by irradiation. TAp63 staining was not seen in control or irradiated tissues.

 Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

p53 pathway responses to radiotherapy in normal human mammary gland. Human mammary tissue xenografts were collected 4 hours after sham irradiation (control) or 5-Gy irradiation and stained for p53, Ser15-phosphorylated p53, p21(CDKN1A), ΔNp63, and activated caspase-3. Positive staining is seen as a brown precipitate, nuclei are stained blue. Note the increase in staining for p53, phospho-p53, p21, and caspase-3 in breast epithelium following irradiation, whereas surrounding stromal cells remain unstained. ΔNp63 is seen in basal epithelial cells at similar levels with or without irradiation.

 Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Dose dependency of p53 pathway responses to ionizing radiation. The response to ionizing radiation was quantified using histoscores of mammary epithelial cells 4 hours after 2- or 5-Gy irradiation. Bars represent the mean histoscore for each endpoint assessed, and the error bars represent the standard deviation.

View this table:
  • View inline
  • View popup
Table 2.

Dose-dependent induction, stabilization, and activation of p53 in breast epithelium

To assess radiation-induced DNA damage, γ-H2AX was used as a marker of DNA double-strand breaks and Rad51 as a marker of repair by homologous recombination. In sham-irradiated tissues, the number of cells showing γ-H2AX foci was extremely low and each positive cell showed only 1 or 2 foci. After 2 and 5-Gy exposure, both the percentage of cells with γ-H2AX foci and the number of foci in each cell was increased in a dose-dependent manner, although the response was not linear and the higher dose led to a much higher level of residual double-strand DNA breaks in a small percentage of cells (Fig. 3). As with the other endpoints measured, there was considerable heterogeneity of response between different patients (note the range of values in different patients in Table 2). γ-H2AX foci were not prominent in stromal cells in any patient at either dose. No Rad51 foci were demonstrated in breast epithelium at either dose, although we have identified Rad51 foci in xenografted tumor cell lines and in irradiated murine hemopoietic cells, using this antibody (unpublished data).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

The accumulation and repair of γ-H2AX foci. Examples of staining following 2- or 5-Gy irradiation, collected 1 or 4 hours postirradiation or after sham irradiation (control). Note that γ-H2AX is seen in the nuclei and shows a dose response and time dependence of staining.

The epithelial response depends on cell type and position in the duct

In vitro studies have shown that myoepithelial cells and ductal cells respond differently to ionizing radiation (19). Consistent with this, the endpoints measured in this study showed a distinct pattern of staining within the ductal epithelium. Most notably, there was a marked variability of staining intensity for p53, phospho-p53, and p21 between basally located and luminal cells within some ducts, as shown in Figure 4. In addition, staining was dependent on the position along the ductal system, with more intense staining in terminal duct lobular units that are most distal from the nipple than in subsegmental ducts that are closer to the nipple (Supplementary Fig. S2).

 Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Differential responses in basal and luminal cells. An example of predominant Ser15-phosphorylated p53 in basal cells 4 hours after 5-Gy irradiation, and 2 examples of p21 localization to basal cells are shown, one removed 4 hours after irradiation and the other removed 1 hour after irradiation.

Time-course studies

Comparison of 1 and 4 hours after exposure to either 2 or 5 Gy showed a similar dose-dependent increase in p53 and phospho-p53 staining in ductal epithelium, although the absolute levels achieved at 1 hour were less than those achieved at 4 hours, results are consistent with those obtained from other studies investigating these effects both in vivo and in vitro (14, 21). In addition, there was no increase in activated caspase-3 staining at 1 hour. Responses were minimal in stromal cells 1 hour postirradiation. This earlier time point allowed us to study the accumulation of γ-H2AX foci, which are rapidly formed at the sites of double-strand DNA breaks and are lost as the breaks are repaired, usually within a few hours (29). Foci of γ-H2AX were readily apparent 1 hour after 2- or 5-Gy exposure, with a higher number of foci visible after the higher dose, as expected (Fig. 3). Unexpectedly, γ-H2AX levels were highly variable in different parts of the same fragments of xenografted tissue. Epithelial cells surrounded by an adipocyte-rich stroma showed more intense staining than cells embedded within a fibroblast-rich stroma (Fig. 5): 12.96% of epithelial cells showed more than 10 foci in fibroblast-rich areas compared with 71.42% of cells in adipocyte-rich areas 1 hour postirradiation. In addition, γ-H2AX was more pronounced in luminal epithelial cells than in basally located cells (Fig. 5).

 Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Effect of surrounding stroma on radiation response of epithelial cells. Different areas of the same piece of tissue show markedly different accumulation of γ-H2AX in mammary epithelial cells, associated with different stromal components. The tissue was removed 1 hour after 5-Gy irradiation.

Discussion

Radiotherapy is commonly used in patients with early-stage breast cancer, but the precise effects of radiation on the normal breast are unknown. We report the development and first use of a xenograft model of normal human breast tissue to study the differential responses of human mammary tissue components to ionizing radiation in vivo. The xenografting method has been demonstrated to provide viable tissues for at least 2 months postengraftment (26, 30) and building on this, our study demonstrates both dose-dependent and time-dependent induction of p53 responses in human breast epithelium. In contrast, the p53 network responses to ionizing radiation previously reported in murine rather than human breast epithelium in vivo initially suggested cytoplasmic sequestration of p53 in the normal, untreated epithelium (not identified in the human epithelium here) and translocation of p53 to the nucleus after irradiation in the presence of placental hormones (31). In subsequent studies, cytoplasmic p53 was not seen but nuclear accumulation after irradiation was associated with the proliferation of epithelial cells and accompanied by both growth arrest and apoptosis (32). In other murine studies, exogenous hormonal treatment (absent in the xenograft model reported here) was, by itself, shown to induce p53 nuclear accumulation. Genotoxic agents induced further accumulation of p53 and p21 (33).

In the current study, we have shown differential responses of human mammary epithelium to therapeutically relevant doses of ionizing radiation. The system maintains the architecture of the human mammary gland and allows interactions between the breast epithelium and breast stroma. Human mammary epithelial cells showed a robust and dose-dependent induction of p53 and apoptosis in the first 4 hours following irradiation. The duration and long-term consequences of this induction have not been addressed in this model but are in keeping with the observed persistent increased expression of p53 even 2 to 5 years after radiotherapy in the “normal” human breast (34). The responses identified in the breast epithelium are typical of self-renewing tissues and are characteristically not induced in nonproliferating cells and tissues (14, 17–19), indicating that breast epithelial cells are a distinct tissue type with respect to radiation responses, and their response may reflect the requirement to maintain proliferative potential even if the epithelium is not actively proliferating at the time of irradiation.

Upstream signals influencing p53 activation include phosphorylation of both the N-terminal serine-15 site, largely mediated by ataxia telangiectasia mutated (ATM), and at the C-terminal serine-392 site involved in enhancing DNA binding (9). Although ATM is redundant for p53 induction and apoptosis in some epithelial cell types such as hair follicles and small intestine (35), our data indicate that p53 Ser15 phosphorylation is important in mammary epithelium and are consistent with the role of ATM in susceptibility to breast cancer (36). We also demonstrate p53 phosphorylation at Ser392, a stress-specific phosphorylation event that, some suggest, may not be induced by ionizing radiation (9). This discrepancy may indicate a cell-type and tissue-context specificity of phosphorylation. A lack of phosphorylation at Ser392 may be important in breast cancer pathogenesis and inability to phosphorylate p53 at this site has been related to treatment response (37).

Although p53 activation was identified in tissue from every patient, the responses in different cell types within an individual were disparate and interindividual variations were noted (Table 2, Figs. 2–5 and Supplementary Figs. S1 and S2). For example, p53 induction was seen in both myoepithelial (basal) and luminal cells, but the phosphorylation of Ser392 and Ser15 was often more prominent in the myoepithelium, indicating cell-type specificity of radiation response, as noted in vitro (21). There were also clear differences in the induction of p21, which was seen more commonly in basally located cells than in luminal cells. That different cell types in the mammary gland respond differently to ionizing radiation is compatible with observations that isolated basal breast epithelial cells proceed to transitory cell cycle arrest whereas luminal cells achieve a more durable G2-M arrest (21). Although the underlying mechanisms for these differential responses are not clear, the presence of the N-terminal-truncated ΔNp63 isoform in basal but not in luminal cells is expected to play a role. The ΔNp63 isoforms lack the classic p53-family transcription activation domain and therefore act as natural antagonists for p53-family activity and inhibit p53-mediated apoptosis in the skin following UV irradiation (38). Following UV irradiation, ΔNp63 is degraded by a ubiquitin-dependent process, thereby allowing p53-mediated responses (38, 39). However, we did not see any evidence for degradation of ΔNp63 in basal mammary epithelium following ionizing radiation exposure, suggesting that this protein could continue to inhibit p53 activity in basal cells. Moreover, ΔNp63 upregulates the ATM kinase responsible for the phosphorylation of p53 Ser15 (40) and induces DNA repair genes including Mre11 and BRCA2 (41), suggesting that expression of ΔNp63 by basal mammary cells is, at least, partly responsible for the differences in phosphorylation and response to ionizing radiation of the basal and luminal breast epithelia. The evidence that basal and luminal cells show distinct p53 pathway responses to ionizing radiation is also in keeping with the observation that breast cancer that develops following therapeutic irradiation during breast maturation in young women shows basal-like differentiation (42) either to an ER negative, HER2-positive phenotype or to a triple-negative phenotype. In addition, the observations that p53 mutations are much more common in basal-like tumors than in luminal cancers also imply that these distinct cell types have different dependencies upon p53 (1).

This mouse xenograft model of short-term radiation responses in normal human breast tissues also permitted assessment of double-strand DNA break repair in vivo. We show an expected accumulation of γ-H2AX foci early in the response, with a rapid decline in the number of foci within 4 hours. Although Rad51 foci have been shown both in xenografted tumor cell lines and in irradiated murine hemopoietic cells with the antibody used here (unpublished data), the absence of detectable Rad51 foci in the present study is in keeping with the nonproliferating breast epithelial and stromal cell populations examined and suggests that repair by homologous recombination is not a key pathway in adult breast epithelium.

Stromal components showed minimal responses to ionizing radiation within the time and dose constraints of this model, even though the dose of radiation was the same in all cells in the tissue. Although stromal gene expression may be important in the induction and maintenance of breast cancer (43), we would not anticipate immune or angiogenic responses to be influential in our model, given the short duration of the experiments and the ablation of the immune system in the murine host. Despite the relative lack of response of stromal cells themselves, we observed dramatic differences in the epithelial response depending on the surrounding stromal composition, pointing to a role for the stroma in determining the response of epithelial cell populations. The role of mammary stroma in regulating the epithelium is well appreciated (44, 45), and adipocytes are known to produce estrogen and a variety of growth factors that influence the ductal epithelium (46, 47). Moreover, the association of breast cancer risk with mammary involution during aging may relate to the differences in stromal composition before and after involution, and there is evidence that premalignant changes to breast epithelium are associated with stromal areas high in connective tissue (as in radiologically dense breasts) rather than adipose-rich areas (48, 49). An important implication of our data relating radiation response to the surrounding stromal architecture is that radiation-induced carcinogenesis in human mammary epithelium may vary according to the stroma. These findings emphasize the requirements to study the correct cell type and cellular context in vivo and question the extrapolation of experimental findings using cultured fibroblasts or lymphocytes to predict the response of human epithelial tissues (7, 50).

In conclusion, although data were not obtained for all patients, this xenograft approach allowed examination of the radiation response of normal breast tissues at 2 time points (1 and 4 hours) after 2 doses (2 and 5 Gy) of radiation in the same patient. This model could be used to study the modifying effects of anticancer drugs on radiation responses in vivo or the effect of breast cancer predisposition genes on the sensitivity of normal breast tissue to genotoxic agents, although interpretation of such studies is likely to be challenging in view of the complexities of response we have uncovered here. Nonetheless, the model offers an integrated (systems- and architecture-based) approach and the preservation of normal anatomic relationships of ductal lobular units and their interactions with the original stromal elements may avoid some of the pitfalls inherent to more conventional techniques using cell-based assays (50–52). We have demonstrated that although breast epithelial cells can be considered to undergo an archetypal p53 pathway response to ionizing radiation exposure, the in vivo responses of individual cell types (basal/luminal), position along the length of the dutcal structure, and the epithelial–stromal relationships are more complex than previously supposed and the clinical implications of this deserve further exploration.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We are grateful to the patients for consenting to the donation of their tissues, to B. Vojtesek and D. Lane for providing antibodies, and to Breast Cancer Research Scotland and the Ninewells Cancer Campaign for funding this work.

Grant Support Funded by Breast Cancer Research Scotland (M.C.V.L. Appleyard and K. Murray) and Ninewells Cancer Campaign (C. Ackland).

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

    P.J. Coates and M.V.C.L. Appleyard contributed equally to this work.

  • Received March 30, 2010.
  • Revision received August 14, 2010.
  • Accepted September 2, 2010.
  • ©2010 American Association for Cancer Research.

References

  1. 1.↵
    1. Stebbing J,
    2. Delaney G,
    3. Thompson AM
    . Clinical Evidence Handbook; Breast Cancer (Non-metastatic). London, UK: BMJ Publishing Group; 2008.
  2. 2.↵
    1. Bentzen SM,
    2. Skoczylas JZ,
    3. Overgaard M,
    4. Overgaard J
    . Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 1996; 88: 918–22.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Vicini FA,
    2. Kestin L,
    3. Chen P,
    4. Benitez P,
    5. Goldstein NS,
    6. Martinez A
    . Limited-field radiation therapy in the management of early-stage breast cancer. J Natl Cancer Inst 2003; 95: 1205–10.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Vaidya JS,
    2. Joseph DJ,
    3. Tobias JS,
    4. Bulsara M,
    5. Wenz F,
    6. Saunders C,
    7. et al.
    Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet 2010; 376: 91–102.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Vaidya JS,
    2. Baum M,
    3. Tobias JS,
    4. D'Souza DP,
    5. Naidu SV,
    6. Morgan S,
    7. et al.
    Targeted intra-operative radiotherapy (Targit): an innovative method of treatment for early breast cancer. Ann Oncol 2001; 12: 1075–80.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Hiley C,
    2. Tutt A,
    3. Torres M,
    4. Palmieri C
    . Adjuvant radiotherapy for breast cancer. BMJ 2009; 338: 4–5.
    OpenUrlCrossRef
  7. 7.↵
    1. Barnett GC,
    2. West CM,
    3. Dunning AM,
    4. Elliott RM,
    5. Coles CE,
    6. Pharoah PD,
    7. et al.
    Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009; 9: 134–42.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Alsner J,
    2. Andreassen CN,
    3. Overgaard J
    . Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008; 18: 126–35.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Appella E,
    2. Anderson CW
    . Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 2001; 268: 2764–72.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Walker RA,
    2. Thompson AM
    1. Staples O,
    2. Lain S,
    3. Ziyaie D
    ,Thompson AM p53 and breast cancer. In: Walker RA, Thompson AM , editors.Prognostic and Predictive Factors in Breast Cancer. London, UK: Informa Health Care; 2008, p. 148–67.
  11. 11.↵
    1. Vogelstein B,
    2. Lane D,
    3. Levine AJ
    . Surfing the p53 network. Nature 2000; 408: 307–10.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Green DR,
    2. Chipuk JE
    . p53 and metabolism: inside the TIGAR. Cell 2006; 126: 30–2.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Vousden KH,
    2. Lane DP
    . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275–83.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Coates PJ,
    2. Lorimore SA,
    3. Lindsay KJ,
    4. Wright EG
    . Tissue-specific p53 responses to ionizing radiation and their genetic modification: the key to tissue-specific tumour susceptibility? J Pathol 2003; 201: 377–88.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Fei P,
    2. Bernhard EJ,
    3. El-Deiry WS
    . Tissue-specific induction of p53 targets in vivo . Cancer Res 2002; 62: 7316–27.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Gottlieb E,
    2. Haffner R,
    3. King A,
    4. Asher G,
    5. Gruss P,
    6. Lonai P,
    7. et al.
    Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J 1997; 16: 1381–90.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Komarova EA,
    2. Chernov MV,
    3. Franks R,
    4. Wang K,
    5. Armin G,
    6. Zelnick CR,
    7. et al.
    Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo . EMBO J 1997; 16: 1391–400.
    OpenUrlAbstract
  18. 18.↵
    1. MacCallum DE,
    2. Hupp TR,
    3. Midgley CA,
    4. Stuart D,
    5. Campbell SJ,
    6. Harper A,
    7. et al.
    The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996; 13: 2575–87.
    OpenUrlPubMed
  19. 19.↵
    1. Midgley CA,
    2. Owens B,
    3. Briscoe CV,
    4. Thomas DB,
    5. Lane DP,
    6. Hall PA
    . Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo . J Cell Sci 1995; 108: 1843–8.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Song S,
    2. Lambert PF
    . Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. Am J Pathol 1999; 155: 1121–7.
    OpenUrlPubMed
  21. 21.↵
    1. Huper G,
    2. Marks JR
    . Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation. Cancer Res 2007; 67: 2990–3001.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Phillips TM,
    2. McBride WH,
    3. Pajonk F
    . The response of CD24(−/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006; 98: 1777–85.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Ponten F,
    2. Lindman H,
    3. Bostrom A,
    4. Berne B,
    5. Bergh J
    . Induction of p53 expression in skin by radiotherapy and UV radiation: a randomized study. J Natl Cancer Inst 2001; 93: 128–33.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Simonsson M,
    2. Qvarnstrom F,
    3. Nyman J,
    4. Johansson KA,
    5. Garmo H,
    6. Turesson I
    . Low-dose hypersensitive gammaH2AX response and infrequent apoptosis in epidermis from radiotherapy patients. Radiother Oncol 2008; 88: 388–97.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Turesson I,
    2. Nyman J,
    3. Qvarnstrom F,
    4. Simonsson M,
    5. Book M,
    6. Hermansson I,
    7. et al.
    A low-dose hypersensitive keratinocyte loss in response to fractionated radiotherapy is associated with growth arrest and apoptosis. Radiother Oncol 2010; 94: 90–101.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Blance RN,
    2. Sims AH,
    3. Anderson E,
    4. Howell A,
    5. Clarke RB
    . Normal breast tissue implanted into athymic nude mice identifies biomarkers of the effects of human pregnancy levels of estrogen. Cancer Prev Res 2009; 2: 257–64.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Laidlaw IJ,
    2. Clarke RB,
    3. Howell A,
    4. Owen AW,
    5. Potten CS,
    6. Anderson E
    . The proliferation of normal human breast tissue implanted into athymic nude mice is stimulated by estrogen but not progesterone. Endocrinology 1995; 136: 164–71.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Nenutil R,
    2. Smardova J,
    3. Pavlova S,
    4. Hanzelkova Z,
    5. Muller P,
    6. Fabian P,
    7. et al.
    Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 2005; 207: 251–9.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Rogakou EP,
    2. Boon C,
    3. Redon C,
    4. Bonner WM
    . Megabase chromatin domains involved in DNA double-strand breaks in vivo . J Cell Biol 1999; 146: 905–16.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. McManus MJ,
    2. Welsch CW
    . Hormone-induced ductal DNA synthesis of human breast tissues maintained in the athymic nude mouse. Cancer Res 1981; 41: 3300–5.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Kuperwasser C,
    2. Pinkas J,
    3. Hurlbut GD,
    4. Naber SP,
    5. Jerry DJ
    . Cytoplasmic sequestration and functional repression of p53 in the mammary epithelium is reversed by hormonal treatment. Cancer Res 2000; 60: 2723–9.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Minter LM,
    2. Dickinson ES,
    3. Naber SP,
    4. Jerry DJ
    . Epithelial cell cycling predicts p53 responsiveness to gamma-irradiation during post-natal mammary gland development. Development 2002; 129: 2997–3008.
    OpenUrlPubMed
  33. 33.↵
    1. Sivaraman L,
    2. Conneely OM,
    3. Medina D,
    4. O'Malley BW
    . p53 is a potential mediator of pregnancy and hormone-induced resistance to mammary carcinogenesis. Proc Natl Acad Sci U S A 2001; 98: 12379–84.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Poeze M,
    2. von Meyenfeldt MF,
    3. Peterse JL,
    4. George WD,
    5. de Jong JM,
    6. Jager JJ,
    7. et al.
    Increased proliferative activity and p53 expression in normal glandular breast tissue after radiation therapy. J Pathol 1998; 185: 32–7.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Gurley KE,
    2. Kemp CJ
    . Ataxia-telangiectasia mutated is not required for p53 induction and apoptosis in irradiated epithelial tissues. Mol Cancer Res 2007; 5: 1312–8.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Renwick A,
    2. Thompson D,
    3. Seal S,
    4. Kelly P,
    5. Chagtai T,
    6. Ahmed M,
    7. et al.
    ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873–5.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Yap DB,
    2. Hsieh JK,
    3. Zhong S,
    4. Heath V,
    5. Gusterson B,
    6. Crook T,
    7. et al.
    Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res 2004; 64: 4749–54.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Liefer KM,
    2. Koster MI,
    3. Wang XJ,
    4. Yang A,
    5. McKeon F,
    6. Roop DR
    . Down-regulation of p63 is required for epidermal UV-B-induced apoptosis. Cancer Res 2000; 60: 4016–20.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Westfall MD,
    2. Joyner AS,
    3. Barbieri CE,
    4. Livingstone M,
    5. Pietenpol JA
    . Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle 2005; 4: 710–6.
    OpenUrlPubMed
  40. 40.↵
    1. Craig AL,
    2. Holcakova J,
    3. Finlan LE,
    4. Nekulova M,
    5. Hrstka R,
    6. Gueven N,
    7. et al.
    DeltaNp63 transcriptionally regulates ATM to control p53 serine-15 phosphorylation. Mol Cancer 2010; 9: 195.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Lin YL,
    2. Sengupta S,
    3. Gurdziel K,
    4. Bell GW,
    5. Jacks T,
    6. Flores ER
    . p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet 2009; 5: e1000680.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Castiglioni F,
    2. Terenziani M,
    3. Carcangiu ML,
    4. Miliano R,
    5. Aiello P,
    6. Bertola L,
    7. et al.
    Radiation effects on development of HER2-positive breast carcinomas. Clin Cancer Res 2007; 13: 46–51.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    1. Finak G,
    2. Bertos N,
    3. Pepin F,
    4. Sadekova S,
    5. Souleimanova M,
    6. Zhao H,
    7. et al.
    Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518–27.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Weigelt B,
    2. Bissell MJ
    . Unraveling the microenvironmental influences on the normal mammary gland and breast cancer. Semin Cancer Biol 2008; 18: 311–21.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Wiseman BS,
    2. Werb Z
    . Stromal effects on mammary gland development and breast cancer. Science 2002; 296: 1046–9.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Hede K
    . Fat may fuel breast cancer growth. J Natl Cancer Inst 2008; 100: 298–9.
    OpenUrlFREE Full Text
  47. 47.↵
    1. Vona-Davis L,
    2. Rose DP
    . Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007; 14: 189–206.
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Radisky DC,
    2. Hartmann LC
    . Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia 2009; 14: 181–91.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Turashvili G,
    2. McKinney S,
    3. Martin L,
    4. Gelmon KA,
    5. Watson P,
    6. Boyd N,
    7. et al.
    Columnar cell lesions, mammographic density and breast cancer risk. Breast Cancer Res Treat 2009; 115: 561–71.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Lopez E,
    2. Guerrero R,
    3. Nunez MI,
    4. del Moral R,
    5. Villalobos M,
    6. Martínez-Galán J,
    7. et al.
    Early and late skin reactions to radiotherapy for breast cancer and their correlation with radiation-induced DNA damage in lymphocytes. Breast Cancer Res 2005; 7: R690–8.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Geara FB,
    2. Peters LJ,
    3. Ang KK,
    4. Wike JL,
    5. Sivon SS,
    6. Guttenberger R,
    7. et al.
    Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation. Cancer Res 1992; 52: 6348–52.
    OpenUrlAbstract/FREE Full Text
  52. 52.↵
    1. Slonina D,
    2. Klimek M,
    3. Szpytma T,
    4. Gasinska A
    . Comparison of the radiosensitivity of normal-tissue cells with normal-tissue reactions after radiotherapy. Int J Radiat Biol 2000; 76: 1255–64.
    OpenUrlCrossRefPubMed
  53. 53.
    1. Blaydes JP,
    2. Craig AL,
    3. Wallace M,
    4. Ball HM,
    5. Traynor NJ,
    6. Gibbs NK,
    7. et al.
    Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene 2000; 19: 3829–39.
    OpenUrlCrossRefPubMed
  54. 54.
    1. Nylander K,
    2. Vojtesek B,
    3. Nenutil R,
    4. Lindgren B,
    5. Roos G,
    6. Zhanxiang W,
    7. et al.
    Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417–27.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Cancer Research: 70 (23)
December 2010
Volume 70, Issue 23
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Differential Contextual Responses of Normal Human Breast Epithelium to Ionizing Radiation in a Mouse Xenograft Model
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Differential Contextual Responses of Normal Human Breast Epithelium to Ionizing Radiation in a Mouse Xenograft Model
Philip J. Coates, M. Virginia, C.L. Appleyard, Karen Murray, Caroline Ackland, June Gardner, Douglas C. Brown, Dougal J.A. Adamson, Lee B. Jordan, Colin A. Purdie, Alastair J. Munro, Eric G. Wright, John A. Dewar and Alastair M. Thompson
Cancer Res December 1 2010 (70) (23) 9808-9815; DOI: 10.1158/0008-5472.CAN-10-1118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Differential Contextual Responses of Normal Human Breast Epithelium to Ionizing Radiation in a Mouse Xenograft Model
Philip J. Coates, M. Virginia, C.L. Appleyard, Karen Murray, Caroline Ackland, June Gardner, Douglas C. Brown, Dougal J.A. Adamson, Lee B. Jordan, Colin A. Purdie, Alastair J. Munro, Eric G. Wright, John A. Dewar and Alastair M. Thompson
Cancer Res December 1 2010 (70) (23) 9808-9815; DOI: 10.1158/0008-5472.CAN-10-1118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • RXRA and PPARG in Bladder Cancer
  • Design of Potent Prodrug Nanoassemblies for Cancer Therapy
  • SOCS1 Improves Radiosensitivity and Enhances DNA Damage
Show more Therapeutics, Targets, and Chemical Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement